pyrazines has been researched along with Epilepsy in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D | 1 |
| Ding, K; Gross, RE; Shiu, FH; Tung, JK | 1 |
| Chońska, J; Dawidowski, M; Mika, W; Turło, J | 1 |
| Dawidowski, M; Lewandowski, W; Turło, J | 1 |
| Li, W; Mei, CW; Xu, MT | 1 |
| Chodkowski, A; Dawidowski, M; Herold, F; Kleps, J | 1 |
| Eller, M; Foreman, MM; Hanania, T; Stables, JP; Stratton, SC; White, HS; Wilcox, KS | 1 |
1 review(s) available for pyrazines and Epilepsy
| Article | Year |
|---|---|
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inducers; Dexamethasone; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Epilepsy; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2 | 2021 |
6 other study(ies) available for pyrazines and Epilepsy
| Article | Year |
|---|---|
Chemically activated luminopsins allow optogenetic inhibition of distributed nodes in an epileptic network for non-invasive and multi-site suppression of seizure activity.
Topics: Animals; Anterior Thalamic Nuclei; Bicuculline; Convulsants; Dentate Gyrus; Epilepsy; Imidazoles; Luminescent Agents; Male; Neural Inhibition; Neural Pathways; Opsins; Optogenetics; Pyrazines; Rats, Sprague-Dawley; Seizures | 2018 |
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Epilepsy; Halogenation; Hydrocarbons, Fluorinated; Male; Mice; Molecular Structure; Pentylenetetrazole; Pilocarpine; Pyrazines; Pyrroles; Rats; Rats, Sprague-Dawley; Seizures; Structure-Activity Relationship | 2014 |
Synthesis of new perhydropyrrolo[1,2-a]pyrazine derivatives and their evaluation in animal models of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Evaluation, Preclinical; Epilepsy; Male; Mice; Molecular Structure; Pyrazines | 2014 |
[Effects of tetramethylpyrazine on the scores of the water maze and the long-term potentiation of hippocampus in epileptic Sprague Dawley rats].
Topics: Animals; Epilepsy; Hippocampus; Long-Term Potentiation; Male; Maze Learning; Phytotherapy; Pyrazines; Rats; Rats, Sprague-Dawley | 2008 |
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 2: Perhydropyrido[1,2-a]pyrazines.
Topics: Animals; Anticonvulsants; Biological Assay; Diketopiperazines; Electroshock; Epilepsy; Magnetic Resonance Spectroscopy; Male; Mice; Molecular Structure; Optical Rotation; Pyrazines; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Structure-Activity Relationship | 2012 |
In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Calcium Channel Blockers; Central Nervous System; Disease Models, Animal; Epilepsy; Humans; Kindling, Neurologic; Lamotrigine; Male; Mice; Molecular Structure; Motor Activity; Pyrazines; Rats; Rats, Sprague-Dawley; Seizures; Sodium Channel Blockers; Triazines | 2008 |